The Real-World Outcomes of Relapsed/Refractory Multiple Myeloma Treated with Elotuzumab, Pomalidomide, and Dexamethasone
<b>Introduction</b>: A combination of elotuzumab, pomalidomide, and dexamethasone (EPd) was approved for the treatment of relapsed/refractory multiple myeloma (RRMM) following the ELOQUENT-3 phase II clinical trial. However, the clinical experience with this therapy is still limited. In this retrosp...
Bewaard in:
| Hoofdauteurs: | , , , , |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
MDPI AG
2024-09-01
|
| Reeks: | Hematology Reports |
| Onderwerpen: | |
| Online toegang: | https://www.mdpi.com/2038-8330/16/4/58 |
| Tags: |
Geen labels, Wees de eerste die dit record labelt!
|